Gastric cancer
Conditions
Interventions
Case series:Nab-paclitaxel, Nedaplatin plus Bevacizumab
Sponsors
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years; 2. Pathologically confirmed lung adenocarcinoma; 3. Patients who have not received systemic chemotherapy before; 4. Not receive other anticancer treatments during the trial; 5. At least one measurable lesion as defined by RECIST 1.1 criteria; 6. Driven gene EGFR,ALK and ROS1 were all negative by the detection method approved by the national CFDA; 7. KPS=70; 8. Expected survival of more than 3 months; 9. Absolute neutrophil count (ANC)=1.5×10^9/L; Platelet count (PLT)=80×10^9/L;Hemoglobin (Hb)=90 g/L; White blood cell(WBC)=4.0×10^9/L;no bleeding symptoms or bleeding tendency; 10. Patients with no other malignant tumors for the past 5 years, unless skin basal cell carcinoma, skin squamous cell carcinoma or any other carcinoma in situ. 11. Patients can understand the situation of the study and has signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Brain metastases or other malignant tumours; 2. II-IV peripheral neuropathy [NCI CTCAE]; 3. Extensive distant metastasis or life expectancy < 3 months; 4. Cancer cachexia or multiple organ failure; 5. For patients who have received radical treatment in the past, new target lesions must be included in the group. For patients who have received local treatment in the past, the original lesion cannot be regarded as the target lesion; 6. Patients who have chronic or acute significant systemic disease; 7. Serious cardiovascular diseases such as cerebrovascular accident, myocardial infarction, hypertension that cannot be controlled after drug intervention, unstable angina, heart failure and arrhythmia that require drug intervention; 8. Suffering from central nervous system diseases such as brain tumor, epilepsy that cannot be controlled by standard treatment, cerebral apoplexy, liver cancer with brain metastasis and hepatic encephalopathy; 9. HCV antibody positive or HBV antibody positive or HIV antibody positive; 10. Allergic to albumin paclitaxel, platinum, bevacizumab; 11. Contraindications to bevacizumab; 12. Patients with uncontrolled or unstable concurrent diseases or mental diseases; 13. Any abnormal hyperplasia of bone marrow and abnormal hematopoietic function; 14. Total bilirubin (TBIL), alanine glutamate transaminase (ALT) and glutamate transaminase (AST) =2.5 x upper limit of normal range (ULN); 15. Renal function Cr=1.5 x upper limit of normal range; 16. Suffering from mental or neurological disorders; 17. Pregnant or lactating female patients; Women of child-bearing age who refuse to accept contraceptive measures; 18. Any other situation that the researcher considered patients are unsuitable for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS;OS;Safty; | — |
Countries
China
Contacts
Public ContactHu Guangyuan
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed